My Ph.D work in Shanghai Institute of Materia Medica, Chinese Academy of Sciences, focused on establishing high throughput screening models for anticancer drugs, and investigating pharmacology of candidate compounds. As a postdoctoral researcher at UConn Health, I was driven to explore the mechanisms and functions of a bioactive lipid, sphingosine-1-phosphate (S1P), and its receptors on tumor growth and progression in pediatric cancers, and further developing new anticancer drugs targeting the sphingolipid pathway. The magical application of RNA-seq in my previous work fascinated me into the realm of genomic medicine.
